Molecular and Cellular Biology · 1998 · 147 citations · 37 references
MedicineCell BiologyMolecular BiologyGene ExpressionMolecular OncologyOncogenesGrowth Factor SignalingOncogene ActivationProto-oncogene ActivationRas Family OncogenesTumor Suppressor Gene InactivationTumor Suppressor GenesHeparin-binding ProteinsHomologyImmediate Early Gene ExpressionImmediate Early GenesLoss Of Negative RegulationOncogene RegulationRetroviral Gene TransferTumor Suppressor P53
By using a model system for cell transformation mediated by the cooperation of the activated H-ras oncogene and the inactivated p53 tumor suppressor gene, rCop-1 was identified by mRNA differential display as a gene whose expression became lost after cell transformation. Homology analysis indicates that rCop-1 belongs to an emerging cysteine-rich growth regulator family called CCN, which includes connective-tissue growth factor, CYR61, CEF10 (v-src inducible), and the product of the nov proto-oncogene. Unlike the other members of the CCN gene family, rCop-1 is not an immediate-early gene, it lacks the conserved C-terminal domain which was shown to confer both growth-stimulating and heparin-binding activities, and its expression is lost in cells transformed by a variety of mechanisms. Ectopic expression of rCop-1 by retroviral gene transfers led to cell death in a transformation-specific manner. These results suggest that rCop-1 represents a new class of CCN family proteins that have functions opposing those of the previously identified members.
37
WAF1, a potential mediator of p53 tumor suppression
Wafik S. El‐Deiry, Takashi Tokino, Victor E. Velculescu et al. · Cell · 1993 · 8.4K citations
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
Manuel Serrano, Athena W. Lin, Mila E. McCurrach et al. · Cell · 1997 · 5.1K citations · Full text
Medicine, Cell Biology, Oncology +10
Glen Dranoff, Elizabeth M. Jaffee, A Lazenby et al. · Proceedings of the National Academy of Sciences · 1993 · 2.8K citations
Medicine, Immunology, Oncology +17